Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
3D Print Addit Manuf ; 10(2): 298-309, 2023 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-37123527

RESUMO

A study of the feasibility of porcelain-based formulations for 3D printing was performed. Based on commercial materials characterization, the binder jetting process properties requirements were defined. Porcelain powder-based formulations were prepared and evaluated with different binder solutions. The powder-binder formulations were characterized (e.g., particle size distribution and wettability of powder, viscosity and surface tension of liquid binder) and showed some different and similar characteristics when compared with commercial materials. The addition of solid (sodium alginate, sucrose) and liquid (glycerol, ethanol) additives in the powder-binder composition improved the experimental printed tests. The effect of binder composition and operating process parameters (binder saturation level, bleed compensation, and printed layer thickness) was analyzed and optimized to obtain a printed saucer with different designs. Results revealed some limitations related to the materials and the technology, thus justifying the introduction of technological improvements. This study showed the possibility to process industrial porcelain powders by additive manufacturing, paving the way for a new development challenge in the productive process of ceramic products.

2.
J Cachexia Sarcopenia Muscle ; 13(5): 2405-2416, 2022 10.
Artigo em Inglês | MEDLINE | ID: mdl-35903892

RESUMO

BACKGROUND: Cabozantinib, a standard of care metastatic renal cell carcinoma (mRCC), may be associated with weight and muscle loss. These effects of new generation VEGFR tyrosine kinase inhibitor on muscle mass loss are poorly described. METHODS: All cabozantinib-treated mRCC patients from January 2014 to February 2019 in our institution were included. Clinical data including weight were collected during therapy. Computed tomography images were centrally reviewed for response assessment, and axial sections at the third lumbar vertebrae were used to measure the total muscle area. Toxicities and cabozantinib outcomes were evaluated. Co-primary endpoints included skeletal muscle loss and weight loss (WL), longitudinally evaluated during treatment. WL has been classified according to CTCAEv5.0: Grade 1 (loss of 5 to <10% of baseline body weight), Grade 2 (loss of 10% to <20% of baseline body weight), and Grades 3-4 (loss >20% of baseline body weight). RESULTS: Patients were mostly men (70.3%), median age was 59.2 (range: 22.0-78.0) years, and median baseline body mass index was 25.0 (range: 16.4-49.3) kg/cm2 . Prognosis according to International Metastatic RCC Database Consortium score was good, intermediate, and poor for 13 (13.0%), 63 (63.0%), and 24 (24.0%) patients, respectively. Out of a total of 120 patients, 101 patients with a median follow-up of 22.3 months (range: 4.5-62.2) were eligible for analysis; 85 experienced muscle loss and muscle loss >10% increased during cabozantinib exposition, especially after 6 months of treatment. At cabozantinib baseline, 71 patients (70.3%) had sarcopenia, and 16/30 (53.3%) non-sarcopenic patients developed sarcopenia during treatment. Baseline sarcopenia was associated with lower response rates (P = 0.031) and higher grades 3-4 toxicities (P = 0.001). Out of 92 patients included in the WL analysis, 44 (47.8%) and 12 (13.0%) experienced grades 2 and 3 WL, respectively. CONCLUSIONS: We report a high incidence of grades 3-4 WL, fourth times higher than reported in prior pivotal trials, and half of the patients developed sarcopenia while on cabozantinib treatment. Weight and muscle mass loss with cabozantinib are underreported and may require further investigations and early management.


Assuntos
Carcinoma de Células Renais , Neoplasias Renais , Sarcopenia , Anilidas , Peso Corporal , Carcinoma de Células Renais/tratamento farmacológico , Carcinoma de Células Renais/patologia , Carcinoma de Células Renais/secundário , Feminino , Humanos , Neoplasias Renais/induzido quimicamente , Neoplasias Renais/tratamento farmacológico , Neoplasias Renais/patologia , Masculino , Pessoa de Meia-Idade , Músculo Esquelético/diagnóstico por imagem , Músculo Esquelético/patologia , Inibidores de Proteínas Quinases/efeitos adversos , Piridinas , Sarcopenia/patologia
3.
Insights Imaging ; 12(1): 24, 2021 Feb 17.
Artigo em Inglês | MEDLINE | ID: mdl-33595746

RESUMO

BACKGROUND: Lung perfusion defects (PDs) have been described in COVID-19 using dual-energy computed tomography pulmonary angiography (DE-CTPA). We assessed the prevalence and characteristics of PDs in COVID-19 patients with suspected pulmonary embolism (PE) and negative CTPA. METHODS: This retrospective study included COVID-19 and non-COVID-19 pneumonia groups of patients with DE-CTPA negative for PE. Two radiologists rated the presence of PD within the lung opacities and analyzed the type of lung opacities and PD pattern (i.e. homogeneous or heterogeneous). The clinical, biological, radiological characteristics including time from first symptoms and admission to DE-CTPA, oxygen requirements, CRP, D-dimer levels, duration of hospital admission and death were compared within the COVID-19 group between patients with (PD +) or without PD (PD-). RESULTS: 67 COVID-19 and 79 non-COVID-19 patients were included. PDs were more frequent in the COVID-19 than in the non-COVID-19 group (59.7% and 26.6% respectively, p < 0.001). Patterns of PDs were different, with COVID-19 patients exhibiting heterogenous PDs (38/40, 95%) whereas non-COVID-19 patients showed mostly homogeneous perfusion defects (7/21 heterogeneous PDs, 33%), p < 0.001. In COVID-19 patients, most consolidations (9/10, 90%) exhibited PDs while less than a third of consolidations (19/67, 28%) had PDs in non-COVID-19 patients. D-dimer, oxygen levels and outcome were similar between COVID-19 PD + and PD- patients; however, time between admission and DE-CTPA was longer in PD + patients (median [IQR], 1 [0-7] and 0 [0-2]; p = 0.045). CONCLUSION: Unlike in bacterial pneumonia, heterogeneous PDs within lung opacities are a frequent feature of COVID-19 pneumonia in PE-suspected patients.

4.
AMIA Annu Symp Proc ; : 924, 2007 Oct 11.
Artigo em Inglês | MEDLINE | ID: mdl-18694024

RESUMO

Personal digital assistants (PDAs) are being increasingly used on the health field, however, there are not many papers guiding a PDA-software development process concerning its usability in health field. This paper presents our experience dealing with PDAs regarding some elements of usability. We have shown that if simple yet extremely important points are to be observed before and during the development process, usability on PDA software can be greatly improved.


Assuntos
Computadores de Mão , Pessoal de Saúde , Avaliação da Tecnologia Biomédica
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa